Cannabis Law Report
NOVEMBER 2, 2021
Earlier this month, the FDA released a seven-page plan to accelerate its research into the safety of cannabis-derived products. Piloting market surveillance tools to monitor unapproved cannabis-derived products and “identify potential safety issues before the issues become mainstream.”
Cannabis Chronicles
MAY 22, 2019
SPOKANE — Researchers at Washington State University are teaming up with the Puyallup Tribe of Indians in an effort to chart the tribe’s outcomes prescribing medicinal marijuana to patients. This partnership with WSU and Qwibil will help us research the safety and efficacy of cannabis as medicine for our patients’ use.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 21, 2021
Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. RYAH Group Inc.
The Cannigma
JULY 1, 2022
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.
Cannabis Law Report
MAY 18, 2022
Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. Validcare contracted with 17 CBD companies and acted as the Contract Research Organization, which included gaining feedback from FDA on the protocol, conducting the study and publishing its results.
Cannabis Law Report
JUNE 4, 2021
– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. The poster presentation of the data was by Dr. Scott Tagawa , a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member. – Phase 2 Trial Underway. Phase 2 trial underway.
Cannabis Law Report
MAY 18, 2022
NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study abstract is available here. The methods for both phases were the same.
Expert insights. Personalized for you.
52 
Let's personalize your content